Aviado · Research
Longevity Daily
Thursday, July 2, 2026
Listen
Today's Brief
Today's digest is unified by a single question: can we actually measure — and reverse — biological aging? The lead story answers with a novel tool: Harvard's Gladyshev lab has built the first aging clock tracking RNA damage, showing rapamycin slows it and Alzheimer's accelerates it. Blood-based Alzheimer's biomarkers are appearing in midlife adults' bloodwork, and a Phase 1 trial is launching to rejuvenate aged immune cells in humans. Meanwhile, a Singapore study adds fresh evidence that dAKG can reverse biological age, and a contamination warning on shilajit is worth heeding.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Alzheimer's Blood Biomarkers Linked to Faster Cognitive Decline Starting in Midlife
Blood-based markers of Alzheimer's neuropathology are associated with worse cognitive performance and accelerated cognitive decline in middle-aged adults — not just the elderly. This matters for health-optimizers in their 40s and 50s: the neurological damage that eventually shows up as dementia may be measurable in blood decades earlier. If this research validates, routine midlife blood biomarker screening could become a critical early-warning tool for brain health.
Read more →Women With Parkinson's Carry Significantly Higher Alzheimer's Amyloid Burden Than Men
Women with Parkinson's disease have higher odds of Alzheimer-related amyloid plaque accumulation than men, independent of age or genetic risk factors, according to new data from the EAN 2026 Congress. Crucially, this greater neuropathological burden didn't translate into higher dementia rates — suggesting female brains may compensate differently, a finding that demands more sex-specific research in neurodegenerative disease.
Read more →Supplements & Compounds
Delayed-Release Alpha-Ketoglutarate (dAKG) Linked to Biological Age Reversal in Singapore Study
Supplementation with delayed-release alpha-ketoglutarate (dAKG) may reverse biological age, according to new research out of Singapore covered by NutraIngredients. AKG is a key metabolic intermediate that declines significantly with age; the delayed-release formulation aims to improve absorption and sustain plasma levels. While further replication is needed, this adds to growing evidence that metabolite-based interventions can move the needle on aging biomarkers.
Read more →Shilajit Is Contaminated With Toxins More Often Than Users Realize, Experts Warn
Experts are sounding the alarm on shilajit — the trending resin supplement popular in manosphere health communities — warning that many products are contaminated with heavy metals and other toxins. The underlying science is mixed: fulvic acid in shilajit shows some promise for brain health and inflammation, but unregulated sourcing makes product quality a serious gamble. If you're using shilajit, third-party tested products from certified suppliers are the minimum standard.
Read more →60% of U.S. Adults Now Take Supplements — and Multivitamins Are Losing Ground to Targeted Compounds
A 25-year JAMA study finds that supplement use has reached 60% of U.S. adults, with a marked shift away from multivitamins toward individual compounds. Vitamin D, zinc, and magnesium saw some of the largest increases — exactly the targeted interventions favored by the longevity-minded consumer. The data reflects a broader cultural move toward evidence-informed, personalized supplementation.
Read more →Research & Papers
Harvard's RNA Damage Clock Detects Alzheimer's Signals Other Tests Miss — and Rapamycin Slows the Rot
Harvard's Gladyshev lab has built the first aging clock derived from RNA damage signatures — not gene expression patterns — showing that transcriptomic deterioration accumulates predictably with age and is partially reversible. The clock detects Alzheimer's disease signals in blood at a strength that conventional expression-based clocks completely miss, suggesting it may be a far more sensitive early-warning tool for neurodegeneration. Critically, both rapamycin and caloric restriction measurably slowed RNA damage accumulation, giving longevity-focused readers a compelling new data point for these interventions. This represents a meaningful advance in aging measurement: we're now tracking not just what cells express, but how badly their RNA is degrading.
Read more →Meta-Analysis of 51 Trials Confirms Antihypertensive Therapy Delivers Lasting Cardiovascular Protection
A sweeping Nature Medicine meta-analysis pooling data from 51 randomized controlled trials confirms that blood pressure-lowering medications provide durable cardiovascular protection — reinforcing that blood pressure control remains one of the highest-leverage longevity interventions available. The analysis links cumulative systolic blood pressure to long-term cardiovascular risk and healthy longevity, underscoring that even modest reductions, maintained over time, compound into significant risk reduction. If you're not actively tracking and managing your blood pressure, this is a strong reminder to start.
Read more →Aviado Research: A New In-Depth Analysis on Longevity Science
Aviado Research's latest review takes an evidence-based look at emerging longevity research, translating findings from primary literature into actionable insights for health-optimizers. This analysis applies the same rigorous framework Aviado brings to all its coverage: careful attention to study design, effect sizes, and what the data actually means in practice.
Read the full Aviado analysis →Lifestyle & Nutrition
GLP-1 Drugs Cut Deaths by 26% and Amputations by 48% in Diabetics With Peripheral Artery Disease
In adults with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists were associated with 26% lower all-cause mortality, 48% fewer amputations, and 36% fewer revascularization procedures compared to metformin. The benefits extend well beyond weight loss, suggesting GLP-1 drugs have direct vascular protective effects. For anyone managing cardiometabolic risk factors, these numbers represent a compelling reason to revisit GLP-1 options with your physician.
Read more →Industry & Policy
First Human Trial to Rejuvenate the Aging Immune System by Clearing Senescent T Cells Is Launching
A landmark Phase 1 trial launching in the coming months will target senescent T cells — the exhausted immune cells that accumulate with age and are a primary driver of immunosenescence. These "zombie" immune cells are linked to chronic inflammation, reduced vaccine efficacy, and increased infection vulnerability in older adults. If the trial succeeds, selectively clearing senescent T cells could become a foundational strategy in longevity medicine.
Read more →